Preview

Вопросы вирусологии

Расширенный поиск

Синтетические пептидные вакцины

https://doi.org/10.18821/0507-4088-2016-61-1-5-8

Полный текст:

Аннотация

В обзоре обобщены современные сведения о разработке и испытанию синтетических пептидных вакцин. Рассмотрены успешные примеры создания специфической защиты в результате иммунизации синтетическими пептидами по разным схемам. Отмечена значимость конформации пептидов для их иммуногенности. Предложена альтернативная стратегия защиты организма от инфекции с применением синтетических пептидов.

Об авторах

О. В. Сергеев
Институт вирусологии им. Д. И. Ивановского ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. почетного академика Н.Ф. Гамалеи» Минздрава России
Россия

Сергеев Олег Витальевич, канд. биол. наук

123098, г. Москва



И. Ф. Баринский
Институт вирусологии им. Д. И. Ивановского ФГБУ «Федеральный научно-исследовательский центр эпидемиологии и микробиологии им. почетного академика Н.Ф. Гамалеи» Минздрава России
Россия
123098, г. Москва


Список литературы

1. Зверев В.В., Семенов Б.Ф., Хаитов Р.М. Вакцины и вакцинация: национальное руководство. M.: ГЭОТАР-Медиа; 2011.

2. Медуницын Н.В. Вакцинология. М.: Триада-Х; 1999.

3. Петров Р.В., Хаитов Р.M. Иммуногены и вакцины нового поколения. Moсква: ГЭОТАР-Медиа; 2011.

4. Roitt I., Brostoff J., Male D. Immunology. 5 th ed. Mosby; 2000.

5. Arnon R., Sela M. Antibodies to a unique region in lysozyme provoked by a synthetic antigen conjugate. Proc. Natl. Acad. Sci. USA. 1969; 62(1): 163-71.

6. Langbeheim H., Arnon R., Sela M. Antiviral effect on MS-2 coliphage obtained with a synthetic antigen. Proc. Natl. Acad. Sci. USA. 1976; 73: 4636-40.

7. Lerner R.A. Tapping the immunological repertoire to produce antibodies of predetermined specificity. Nature. 1982; 299: 593-6.

8. Bittle J.L., Houghten R.A., Alexander H., Shinnick T.M., Sutcliffe J.G., Lerner R.A. et al. Protection against foot-and-mouth disease immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature. 1982; 298(5869): 30-3.

9. Brown F. Use of peptides for immunization against foot-and-mouth disease. Vaccine. 1988; 6: 180-2.

10. Doel T.R., Gale C., Do Amaral C.M., Mulcahy G., Dimarchi R. Heterotypic protection induced by synthetic peptides corresponding to three serotypes of foot-and-mouth disease vims. J. Virol. 1990; 64(5): 2260-4.

11. Steward M.W., Stanley C.M., Dimarchi R. High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease. Immunology. 1991; 72: 99-103.

12. Taboga O., Tami C., Carillo E., Núñez J.I., Rodríguez A., Saíz J.C. et al. A large-scale evaluation of peptide vaccines against foot-andmouth disease: lack of solid protection in cattle and isolation of escape. J. Virol. 1997; 71(4): 2606-14.

13. Wang C.Y., Chang T.Y., Walfield A.M., Ye J., Shen M., Chen S.P. et al. Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine. 2002; 20(19-20): 2603-10.

14. Rodriguez L.L., Barrera J., Kramer E., Lubroth J., Brown F., Golde W.T. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine. 2003; 21(25-26): 3751-6.

15. Li G., Chen W., Yan W. Comparison of immune responses against foot-and-mouth disease virus induced by fusion proteins using the swine IgG heavy chain constant region or beta-galactosidase as a carrier of immunogenic epitopes. Virology. 2004; 328: 274-81.

16. Green N., Alexander H., Olson A., Alexander S., Shinnick T.M., Sutcliffe J.G. et al. Immunogenic structure of the influenza haemagglutinin. Cell. 1982; 28(3): 477-87.

17. Muller S., Plaue S., Samama J.P., Valette M., Briand J.P., Van Regenmortel M.H. Antigenic property and protective capacity of a cyclic peptide corresponding to site A of influenza vims haemagglutinin. Vaccine. 1990; 8(4): 308-14.

18. Friede M., Muller S., Briand J.P., Plaué S., Fernandes I., Frisch B. et al. Selective induction of protection against influenza virus infection in mice by a lipid-peptide conjugate delivered in liposomes. Vaccine. 1994; 12(9): 791-7.

19. Ninomiya A., Ogasawara K., Kajino K., Takada A., Kida H. Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice. Vaccine. 2002; 20(25-26): 3123-9.

20. Ma J.H., Yang F.R., Yu H., Zhou Y.J., Li G.X., Huang M. et al. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge. Virol. J. 2013; 10: 227.

21. Geerligs H.J., Weijer W.J., Welling G.W., Welling-Wester S. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-12 of herpes simplex virus type 1 glycoprotein D. J. Immunol. Methods. 1989; 124(1): 95-102.

22. Brynestad K., Babbit B., Huang L., Rouse B.T. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines. J. Virol. 1990; 64(2): 680-5.

23. Langeveld J.P., Casal J.I., Osterhaus A.D., Cortés E., de Swart R., Vela C. et al. First peptide vaccine providing protection against viral infection in the target animal: studies of canine parvovirus in dogs. J. Virol. 1994; 68(7): 4506-13.

24. Takano T., Tomizawa K., Morioka H., Doki T., Hohdatsu T. Evaluation of protective efficacy of the synthetic peptide vaccine containing the T-helper 1 epitope with CpG oligodeoxynucleotide against feline infectious peritonitis virus infection in cats. Antivir. Ther. 2014; 19(7): 645-50.

25. Talbot P.J., Dionne J., Lacroix M. Vaccination against lethal coronavirus-induced encephalitis with a synthetic decapeptide homologous to a domain in the predicted peplomer stalk. J. Virol. 1988; 62: 3032-6.

26. Dietzschold В., Gore M., Marchadier D., Niu H.S., Bunschoten H.M., Otvos L.Jr. et al. Structural and immunological characterization of linear virus-neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J. Virol. 1990; 64(8): 3804-9.

27. Kao D.J., Hodges R.S. Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa. Chem. Biol. Drug Des. 2009; 74(1): 33-42.

28. Serna C., Lara J.A., Rodrigues S.P., Marques A.F., Almeida I.C., Maldonado R.A. A synthetic peptide from Trypanosoma cruzi mucinlike associated surface protein as candidate for a vaccine against Chagas disease. Vaccine. 2014; 32(28): 3525-32.

29. Sirima S.B., Tiono A.B., Ouedraogo A., Diarra A., Ouédraogo A.L., Yaro J.B. et al. Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One. 2009; 4(10): e7549.

30. Nardin E. The past decade in malaria synthetic peptide vaccine clinical trials. Hum. Vaccin. 2010; 6(1): 27-38.

31. Hansen M.R., Villar H.O., Feyfant E. Development of an informatics platform for therapeutic protein and peptide analytics. J. Chem. Inf. Model. 2013; 53(10):2774-9.

32. Волгарева Г.М., Сафронова Л.Д. Контроль генетических последствий вакцинаций: электронно-микроскопический анализ синаптонемных комплексов мыши. Генетика. 1991; 27: 1410-22.

33. Genghini R., Tiranti I., Segade G., Amado J., Wittouck P., Mian L. In vivo effect on pig 9 chromosomes of high dosage vaccine against classic swine fever. Mutat.Res. 1998; 422(2): 357–65.

34. Genghini R., Tiranti I., Bressan E., Zamorano-Ponce E., Fernández J., Dulout F. Determination of genotoxicity of classical swine fever vaccine in vitro by ytogenetic and comet tests. Mutagenesis. 2006; 21(3): 213–7.

35. Sutter R.W. Poliomyelitis vaccines. In: Plotkin S., Orenstein W., Offit P., eds. Vaccines. 5 th ed. Saunders Elsevier; 2008: 62-101.

36. Sergeev V.A., Sergeyev O.V. Hypervaccination as prompt nonimmune protection. Procedia in Vaccinology. 2014; 8: 77 – 88.


Для цитирования:


Сергеев О.В., Баринский И.Ф. Синтетические пептидные вакцины. Вопросы вирусологии. 2016;61(1):5-8. https://doi.org/10.18821/0507-4088-2016-61-1-5-8

For citation:


Sergeyev O.V., Barinsky I.F. Synthetic peptide vaccines. Problems of Virology. 2016;61(1):5-8. (In Russ.) https://doi.org/10.18821/0507-4088-2016-61-1-5-8

Просмотров: 1578


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0507-4088 (Print)
ISSN 2411-2097 (Online)